Foundation to host Investor Briefings on Access to Medicine Index 2024

The Access to Medicine Index ranks 20 of the world’s largest research-based pharmaceutical companies based on how they manage risks and opportunities related to access to medicine and global health. The Index measures a range of value drivers within the pharmaceutical business, including pricing models, R&D, governance and compliance. To date, 148 institutional investors collectively managing over USD 22 trillion, have signed the Access to Medicine Index Investor Statement and use the Index findings and insights in a variety of ways to inform investment-decision making and direct engagement. 

The Access to Medicine Foundation will host a series of Investor Briefings to equip investors with key insights and strategic guidance for engaging with the pharmaceutical industry. These sessions will create new opportunities to influence companies advancing health equity and access in LMICs. 

Conducted by the Foundation's Investor Engagement team, the Briefings draw from the 2024 Index’s findings, offering a comprehensive overview of findings, industry trends, company performance, and opportunities for collaboration. The Briefings on various companies analysed in the 2024 Index will take place between February and July 2025. The schedule is as follows: 

February 

27: Bristol Myers Squibb and Eli Lilly & Co

March 

11: Gilead Sciences and Merck KgGA 
27: Novo Nordisk A/S and AstraZeneca plc

April 

10: Bayer AG and Pfizer Inc
24: Sanofi and GSK plc

May

8: Takeda Pharmaceutical Co, Ltd and AbbVie Inc
22: Daiichi Sankyo Co, Ltd and Merck & Co, Inc. 

June

11: Eisai Co, Ltd and Roche Holding AG
26: Astellas Pharma Inc and Johnson & Johnson

July

10: Novartis AG

Sign up and join the Access to Medicine Foundation Investor Briefings to gain key insights from the 2024 Index. For more information, please contact: